Open Actively Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease


Brief Summary

COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).

COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.

Primary Purpose
Study Type


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Inclusion Criteria:

  • Patients presenting with STEMI or type 1 NSTEMI and within 72 hours of successful culprit-lesion PCI
  • Residual coronary artery disease defined as at least 1 additional non-infarct-related coronary artery stenosis that meets all of the following criteria:
    • Amenable to successful treatment with PCI
    • At least 50% diameter stenosis by visual estimation
    • At least 2.5 mm in diameter
  • Planned complete revascularization strategy for qualifying MI

Exclusion Criteria:

  • Planned or prior coronary artery bypass graft (CABG) surgery
  • Inability to clearly identify a culprit lesion for STEMI or NSTEMI based on angiographic appearance and/or ECG changes and/or regional wall motion abnormalities
  • Prior PCI of a non-culprit lesion in a different vessel from the culprit lesion within 45 days of randomization
  • Planned medical treatment of all qualifying non-culprit lesions (i.e., no PCI)
  • Presence of severe non-culprit-lesion stenosis with reduced epicardial flow (TIMI flow ≤ 2) or >90% visual diameter stenosis
  • Presence of a chronic total occlusion (CTO) if it is the only qualifying non-culprit lesion (patients with a CTO plus additional qualifying non-culprit lesions are eligible)
  • The only qualifying non-culprit lesion is in the same vessel territory as the culprit lesion
  • Baseline STEMI or NSTEMI was due to a suspected non-atherothrombotic mechanism such as type 2 MI (supply-demand mismatch), including spontaneous coronary artery dissection or coronary artery embolism
  • Non-cardiovascular co-morbidity with expected life expectancy <2 years
  • Any other medical, geographic, or social factor making study participation impractical or precluding 5 year follow-up

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Heart/Cardiovascular Diseases
Ladda Douangvila-Chhan
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit